Brief: Aclaris Therapeutics Announces Top-Line Results From 4-Week Phase 2B Trial Of ATI-1777 For Mild To Severe Atopic Dermatitis

Aclaris Therapeutics

10/01/2024 12:43

Jan 10 (Reuters) - Aclaris Therapeutics Inc  ACRS.O :
    * ACLARIS THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM
4-WEEK
PHASE 2B TRIAL OF ATI-1777 FOR MILD TO SEVERE ATOPIC DERMATITIS
    * ACLARIS THERAPEUTICS INC - ATI-1777 2% BID ACHIEVED A
STATISTICALLY SIGNIFICANT RESULT IN PRIMARY EFFICACY ENDPOINT AT
WEEK 4
    * ACLARIS THERAPEUTICS INC - ATI-1777 WAS WELL TOLERATED
    * ACLARIS THERAPEUTICS INC - MINIMAL SYSTEMIC EXPOSURE
SUPPORTS
"SOFT" TOPICAL JAK INHIBITOR APPROACH
    * ACLARIS THERAPEUTICS INC - NO MEANINGFUL SAFETY FINDINGS
WERE
OBSERVED

Source text for Eikon:  ID:nGNX3R9DP0 
Further company coverage:  ACRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))